Smith & Nephew restructuring turns profits round
This article was originally published in Clinica
Smith & Nephew, which is in the throes of re-organising on product, rather than regional lines, reported underlying growth of 5% and a 7% increase in underlying profit, as the market in Europe and the US eased after a number of years of price constraint and cost-cutting.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.